| Name | Wesley Park Centre |
|---|---|
| Location | 500 First Street North, Newton, Iowa |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 66 |
| Occupancy Rate | 89.7% |
| Medicare ID (CCN) | 165543 |
| Legal Business Name | Wesley Retirement Services Inc |
| Ownership Type | Non Profit - Other |
| NPI Number | 1144331679 |
| Organization Name | WESLEY RETIREMENT SERVICES, INC |
| Doing Business As | WESLEY PARK CENTRE |
| Address | 500 1st St N, Newton, IA 50208 |
| Phone Number | 641-791-5000 |
News Archive
Medivation, Inc. and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with chemotherapy. The companies also announced that clinical development of MDV3100 in Japan has commenced, with the initiation of patient dosing in a Phase 1-2 clinical study.
C hemoradiation is superior to chemotherapy alone with respect to both survival and quality of life in patients with inoperable non-small-cell lung cancer, a phase III trial has found.
HIV incidence among African-American men is nearly eight times that of white men, and twice that of Latino men. Incarceration, which disproportionately affects African-American men, is thought to be a factor in this wide disparity.
Viking Systems, Inc. announced today that its recently released 3DHD Vision System has been named a "Best of What's New 2010" award winner in the Health category by Popular Science magazine. The award recipients were included in the December issue of the magazine.
Seth Lederman, M.D., President and CEO of New York City-based Tonix Pharmaceuticals Holding Corp. (OTCBB:TNXP) says that a good night's sleep is a potentially powerful, but currently elusive, treatment for the chronic pain and sleep disorders suffered by patients with fibromyalgia (FM), post-traumatic stress disorder (PTSD), traumatic brain injury (TBI) and chronic traumatic encephalopathy (CTE).
› Verified 4 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Medivation, Inc. and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with chemotherapy. The companies also announced that clinical development of MDV3100 in Japan has commenced, with the initiation of patient dosing in a Phase 1-2 clinical study.
C hemoradiation is superior to chemotherapy alone with respect to both survival and quality of life in patients with inoperable non-small-cell lung cancer, a phase III trial has found.
HIV incidence among African-American men is nearly eight times that of white men, and twice that of Latino men. Incarceration, which disproportionately affects African-American men, is thought to be a factor in this wide disparity.
Viking Systems, Inc. announced today that its recently released 3DHD Vision System has been named a "Best of What's New 2010" award winner in the Health category by Popular Science magazine. The award recipients were included in the December issue of the magazine.
Seth Lederman, M.D., President and CEO of New York City-based Tonix Pharmaceuticals Holding Corp. (OTCBB:TNXP) says that a good night's sleep is a potentially powerful, but currently elusive, treatment for the chronic pain and sleep disorders suffered by patients with fibromyalgia (FM), post-traumatic stress disorder (PTSD), traumatic brain injury (TBI) and chronic traumatic encephalopathy (CTE).
› Verified 4 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 12.57 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 5.62 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 30.51 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.48 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.01 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 4.62 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.49 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 14.43 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 95.79 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.64 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 24.63 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 20 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 9.23 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.21 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 74.94 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 90.43 | 82.93 |
News Archive
Medivation, Inc. and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with chemotherapy. The companies also announced that clinical development of MDV3100 in Japan has commenced, with the initiation of patient dosing in a Phase 1-2 clinical study.
C hemoradiation is superior to chemotherapy alone with respect to both survival and quality of life in patients with inoperable non-small-cell lung cancer, a phase III trial has found.
HIV incidence among African-American men is nearly eight times that of white men, and twice that of Latino men. Incarceration, which disproportionately affects African-American men, is thought to be a factor in this wide disparity.
Viking Systems, Inc. announced today that its recently released 3DHD Vision System has been named a "Best of What's New 2010" award winner in the Health category by Popular Science magazine. The award recipients were included in the December issue of the magazine.
Seth Lederman, M.D., President and CEO of New York City-based Tonix Pharmaceuticals Holding Corp. (OTCBB:TNXP) says that a good night's sleep is a potentially powerful, but currently elusive, treatment for the chronic pain and sleep disorders suffered by patients with fibromyalgia (FM), post-traumatic stress disorder (PTSD), traumatic brain injury (TBI) and chronic traumatic encephalopathy (CTE).
› Verified 4 days ago
Accura Healthcare Of Newton West, Llc Location: 2130 West 18th Street South, Newton, Iowa 50208 Phone: (641) 791-1127 | |
Accura Healthcare Of Newton East, Llc Location: 1743 South Eighth Avenue East, Newton, Iowa 50208 Phone: (641) 792-5680 | |
Newton Health Care Center Location: 200 South Eighth Avenue East, Newton, Iowa 50208 Phone: (641) 792-7440 | |
Newton Village Health Care Center Location: 114 N 5th Avenue W, Newton, Iowa 50208 Phone: (641) 792-0115 |